Spark Therapeutics, Inc. Common Stock
ONCE
ONCE was delisted on the 16th of December, 2019.
90 hedge funds and large institutions have $623M invested in Spark Therapeutics, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 14 funds opening new positions, 38 increasing their positions, 24 reducing their positions, and 32 closing their positions.
58% more repeat investments, than reductions
Existing positions increased: 38 | Existing positions reduced: 24
1.34% more ownership
Funds ownership: 59.11% → 60.45% (+1.3%)
6% more capital inflows, than outflows
Capital inflows: $157M | Capital outflows: $148M
17% less funds holding
Funds holding: 109 → 90 (-19)
42% less call options, than puts
Call options by funds: $20.1M | Put options by funds: $34.7M
56% less first-time investments, than exits
New positions opened: 14 | Existing positions closed: 32
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$45.3M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$16.5M |
| 3 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
+$15.3M |
| 4 |
HCMT
Highland Capital Management (Texas)
Dallas,
Texas
|
+$10.9M |
| 5 |
State Street
Boston,
Massachusetts
|
+$9.71M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deerfield Management
New York
|
-$38M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
-$11.5M |
| 3 |
OrbiMed
New York
|
-$10M |
| 4 |
GGHC
Gilder Gagnon Howe & Co
New York
|
-$9.42M |
| 5 |
Millennium Management
New York
|
-$8.88M |
ONCE Hedge Fund Activity: Q3 2015 in Review
90 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Spark Therapeutics, Inc. Common Stock (ONCE) for Q3 2015, worth a combined $623M — down 29% from $872M a quarter earlier.
Sellers outnumbered buyers: 32 funds closed out of ONCE and 14 opened new positions — a net loss of 18 holders — while 24 trimmed existing stakes and 38 added.
The largest buyer was Fidelity Investments, adding an estimated $45.3M. The largest seller was Deerfield Management, exiting entirely with an estimated $38M sold.
- 90 institutional investors held Spark Therapeutics, Inc. Common Stock (ONCE) as of Q3 2015, down from 109 in Q2 2015.
- Funds reported $623M of Spark Therapeutics, Inc. Common Stock stock for Q3 2015, down 29% quarter-over-quarter.
- 14 funds opened new Spark Therapeutics, Inc. Common Stock positions in Q3 2015 and 32 closed out, a net change of -18 holders.
- The largest Spark Therapeutics, Inc. Common Stock buyer in Q3 2015 was Fidelity Investments, an estimated $45.3M added.
- The largest Spark Therapeutics, Inc. Common Stock seller in Q3 2015 was Deerfield Management, an estimated $38M sold.
Based on aggregated 13F filings for Q3 2015.